Drugs / CNA3103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05759728 | Oct 2023 → Dec 2027 expected | colorectal cancer | Carina Biotech Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2023-08-25 | Carina Biotech Limited | Results PRESS RELEASE: Carina Biotech to Present Preclinical Data at 8th CAR-TCR Summit carinabiotech.com ↗
LGR5-targeting CAR-T cells effectively kill LGR5-expressing cancer cells in in vitro cytotoxicity assays and display significant anti-tumor activity in vivo in a subcutaneous human colorectal cancer xenograft mouse model. |
| 2023-02-07 | Carina Biotech Limited | Results PRESS RELEASE: Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T Cell Therapy Platform in Ovarian Cancer Tumor Models carinabiotech.com ↗
The data shows that LGR5 CAR-T cells have significantly higher killing effects on OVCAR3 (an ovarian cancer cell line) and primary ovarian cancer cells compared to control T cells. |
| 2023-01-24 | Carina Biotech Limited | Regulatory Carina receives ‘Safe to proceed’ letter for Phase 1/2a clinical trial of CNA3103 carinabiotech.com ↗
Receives greenlight from the FDA for Phase 1/2a clinical trial of CNA3103 |
| 2022-12-15 | Carina Biotech Limited | Regulatory Carina Biotech submits an Investigational New Drug (IND) application to the US FDA for LGR5-Targeted CAR-T Cell Therapy Candidate carinabiotech.com ↗
has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for first-in-human Phase 1/2a clinical trial of CNA3103, its LGR5-targeted chimeric antigen receptor T cell (CAR-T) therapy candidate, in patients with advanced colorectal cancer. |
| 2022-04-01 | Carina Biotech Limited | Regulatory Carina Biotech submits LGR5 CAR-T pre-IND (Investigational New Drug) package to the US Food & Drug Administration carinabiotech.com ↗
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food & Drug Administration) for our CAR-T therapy that targets a cancer stem cell antigen known as LGR5. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-25 | Carina Biotech Limited | PRESS RELEASE: Carina Biotech to Present Preclinical Data at 8th CAR-TCR Summit carinabiotech.com ↗ |
| 2023-02-07 | Carina Biotech Limited | PRESS RELEASE: Carina Biotech to Present Preclinical Data at Lorne Cancer 2023 Supporting Effectiveness of LGR5-Targeted CAR-T Cell Therapy Platform in Ovarian Cancer Tumor Models carinabiotech.com ↗ |
| 2023-01-24 | Carina Biotech Limited | Carina receives ‘Safe to proceed’ letter for Phase 1/2a clinical trial of CNA3103 carinabiotech.com ↗ |
| 2022-12-15 | Carina Biotech Limited | Carina Biotech submits an Investigational New Drug (IND) application to the US FDA for LGR5-Targeted CAR-T Cell Therapy Candidate carinabiotech.com ↗ |
| 2022-04-01 | Carina Biotech Limited | Carina Biotech submits LGR5 CAR-T pre-IND (Investigational New Drug) package to the US Food & Drug Administration carinabiotech.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNA3103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05759728 ↗ |
| Modality | Cell therapy | “CNA3103 (Leucine-rich repeat-containing G protein-coupled receptor 5 \[LGR5\]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells)” NCT05759728 ↗ |
| Route | Intravenous | “Participants will receive a single Intravenous dose of CNA3103.” NCT05759728 ↗ |
| Target | LGR5 | “LGR5\]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells” NCT05759728 ↗ |